Pfizer v. Ajanta Pharma: Xeljanz XR Tofacitinib Suit Dismissed Without Prejudice
Pfizer and four co-plaintiffs filed a patent infringement action in the Delaware District Court against Indian generic manufacturer Ajanta Pharma over Xeljanz XR (tofacitinib citrate extended-release tablets). The case was voluntarily dismissed without prejudice under Rule 41(a)(1)(A)(i) just 66 days after filing — before Ajanta had served any answer or motion.
Filing to Case Dismissed in 66 days
66 days — resolved well before typical ANDA litigation timelines of 2–3 years
Without-prejudice dismissal: what Rule 41(a)(1)(A)(i) means for both sides
Rule 41(a)(1)(A)(i): unilateral dismissal before the defendant answers
Under Rule 41(a)(1)(A)(i), a plaintiff may voluntarily dismiss an action as of right — without a court order — provided the defendant has not yet served an answer or a motion for summary judgment. Pfizer invoked this provision explicitly. The dismissal is self-executing: the case closes immediately upon filing the notice, with no judicial approval required and no adverse judgment entered against either party.
Procedural exit, no merits rulingWithout prejudice: Pfizer can refile — but the public record is silent on why
A without-prejudice dismissal leaves Pfizer’s infringement claims legally intact. The company may refile the same claims against Ajanta Pharma — in Delaware or another forum — at a future date, subject to any applicable statute of limitations. The public record does not reveal whether a licensing agreement, a covenant not to sue, a change in Ajanta’s ANDA status, or commercial strategy drove the decision. Each scenario carries meaningfully different implications for Ajanta’s path to market.
Refile right preservedAjanta Pharma exits without a merits win — and without a final license
Ajanta Pharma had not served an answer at the time of dismissal, meaning no invalidity or non-infringement defenses were placed on the record. The dismissal provides no legal protection equivalent to a judgment in Ajanta’s favour. Until Pfizer grants an express licence or covenant, USRE041783E remains a live threat against Ajanta’s Xeljanz XR generic. Ajanta’s commercial timeline for the 11 mg and 22 mg strengths is likely unchanged by this procedural outcome alone.
No licence confirmed on recordANDA challengers: early Hatch-Waxman dismissals often signal off-record deals
In Hatch-Waxman litigation, Rule 41(a)(1)(A)(i) dismissals filed before the defendant answers frequently precede or accompany confidential settlement or licence agreements. Patent practitioners monitoring tofacitinib generics should treat this dismissal as a signal to track any subsequent Ajanta ANDA approval or market entry date, which would confirm whether an agreed launch window was negotiated. Competitors filing ANDAs on Xeljanz XR should assess USRE041783E independently.
Watch Ajanta ANDA approval datesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | PF Prism C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | C.P. Pharmaceuticals International C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Pbg Puerto Rico, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | PF Prism Ibm C.V. | Individual | Search in Eureka ↗ |
| Defendant | Ajanta Pharma | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice explicitly invokes Rule 41(a)(1)(A)(i) and confirms Ajanta had not served an answer or summary judgment motion — the two statutory conditions that make unilateral dismissal available as of right. This precise language matters: it forecloses any argument that the dismissal required court approval or carried implied prejudice. No merits findings were made. USRE041783E’s validity and Ajanta’s infringement exposure remain legally undetermined. The notice’s silence on any licence, covenant, or settlement means the commercial terms — if any exist — are confidential.
USRE041783E — tofacitinib citrate extended-release tablet formulations
USRE041783E is a United States reissue patent, indicated by the ‘RE’ prefix, which means it was granted through the USPTO reissue process to correct or refine claims in an original patent. The corrected application number US12/577790 places its origins in a 2009 filing window. The patent covers tofacitinib citrate extended-release tablet formulations — specifically the 11 mg and 22 mg dosage strengths marketed as Xeljanz XR, a JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
As a reissue patent, USRE041783E may carry claims that differ meaningfully from the original grant, potentially encompassing a wider range of extended-release formulations. This is strategically significant: any generic manufacturer seeking ANDA approval for tofacitinib extended-release products must contend with reissue claims, not simply the original patent family. With Xeljanz XR representing a substantial portion of Pfizer’s rheumatology revenue, enforcement of this patent against ANDA filers is commercially motivated and likely to continue against other challengers.
Should you run an FTO analysis against USRE041783E before entering the tofacitinib ER market?
Any company developing, manufacturing, or filing an ANDA for a tofacitinib extended-release oral tablet — in any dosage strength — should treat USRE041783E as a primary FTO target. The patent’s reissue status means its claims may have been strategically broadened and should be mapped carefully. The fact that Pfizer assembled a five-entity plaintiff group to assert this patent signals it will be actively enforced. R&D teams working on JAK inhibitor ER formulations more broadly should also assess the patent’s claim boundaries.
PatSnap Eureka’s FTO Search Agent allows you to run structured freedom-to-operate searches against USRE041783E and the broader tofacitinib extended-release patent landscape. Eureka surfaces related formulation patents, maps Pfizer’s affiliate ownership chain, and flags ANDA-related litigation across the portfolio — giving IP and regulatory teams a consolidated view of clearance risk before any filing or commercial launch decision.
Run a freedom-to-operate analysis on USRE041783E to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman tofacitinib and JAK inhibitor patent cases
Cases below share key features with this Delaware District Court Hatch-Waxman action: tofacitinib or JAK inhibitor patents, ANDA challengers, and early-stage voluntary dismissals.
What this case signals for the tofacitinib generic IP landscape
A 66-day pre-answer dismissal in a Hatch-Waxman action rarely reflects a clean break — it typically signals a negotiated resolution or a strategic repositioning.
USRE041783E remains enforceable against all non-licenced Xeljanz XR generics
The without-prejudice dismissal confers no estoppel and no implied licence on Ajanta or any other ANDA filer. Companies holding or pursuing Paragraph IV certifications against USRE041783E should conduct independent FTO analysis — this case resolves nothing on the merits and does not narrow the patent’s scope.
Pre-answer timing is the diagnostic signal in Hatch-Waxman dismissals
Pfizer filed and dismissed within 66 days, before Ajanta answered. This pattern is consistent with a confidential licence or agreed-entry negotiation completed off the court record. IP teams at generic manufacturers should monitor Ajanta’s ANDA approval and any subsequent 180-day exclusivity trigger as the next data point confirming whether a deal was reached.
Pfizer v Ajanta — key questions answered
The without-prejudice dismissal means Pfizer’s infringement claims were dropped without any court ruling on the merits. Pfizer retains the full legal right to refile the same claims against Ajanta Pharma at a future date. No judgment was entered, no invalidity finding was made, and USRE041783E remains fully enforceable against any party not holding an express licence or covenant.
USRE041783E is a USPTO reissue patent covering tofacitinib citrate extended-release tablet formulations (Xeljanz XR). Reissue patents may carry claims that differ from the original grant — potentially broader or narrower. In ANDA litigation, this matters because generic manufacturers must design around or challenge the reissue claims specifically, not just the original patent. Failure to account for reissue claim scope is a common FTO gap.
The case resolved in 66 days, well before Ajanta served an answer. This timing is consistent with either a confidential licensing agreement, a covenant not to sue, or a strategic decision by Pfizer to defer litigation. In Hatch-Waxman actions, pre-answer dismissals of this speed typically suggest off-record commercial negotiations, though the public record in this case is silent on the specific reason.
No. The without-prejudice dismissal in Pfizer v. Ajanta Pharma has no preclusive effect on other ANDA filers. USRE041783E remains a live, enforceable patent. Any other company holding a Paragraph IV certification or ANDA for tofacitinib extended-release tablets remains independently exposed to infringement claims. Each ANDA filer’s risk must be assessed on its own merits against the patent’s current claim scope.
The plaintiffs are Pfizer Inc., PF Prism C.V., C.P. Pharmaceuticals International C.V., PBG Puerto Rico LLC, and PF Prism IMB B.V. This multi-entity structure is typical in pharmaceutical IP where manufacturing, commercialisation, and IP holding functions are split across affiliates. It signals that USRE041783E is held or exclusively licensed across a layered corporate structure — relevant for any generic company assessing the full scope of parties that could sue them.
PatSnap Eureka searches patents and litigation data to answer instantly.